Schildkraut J - Search Results

1

Matrix metalloproteinase-1 gene promoter polymorphism and risk of ovarian cancer.

Wenham RM, Calingaert B, Ali S, McClean K, Whitaker R, Bentley R, Lancaster JM, Schildkraut J, Marks J, Berchuck A. Wenham RM, et al. Among authors: schildkraut j. J Soc Gynecol Investig. 2003 Sep;10(6):381-7. doi: 10.1016/s1071-5576(03)00141-2. J Soc Gynecol Investig. 2003. PMID: 12969782

2

Oral contraceptive pills. Prevention of ovarian cancer and other benefits.

Berchuck A, Schildkraut J. Berchuck A, et al. Among authors: schildkraut j. N C Med J. 1997 Nov-Dec;58(6):404-7; discussion 408. N C Med J. 1997. PMID: 9392951 Review.

3

Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk.

Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC. Schildkraut JM, et al. J Natl Cancer Inst. 2002 Jan 2;94(1):32-8. doi: 10.1093/jnci/94.1.32. J Natl Cancer Inst. 2002. PMID: 11773280

4

Pre-counseling education materials for BRCA testing: does tailoring make a difference?

Skinner CS, Schildkraut JM, Berry D, Calingaert B, Marcom PK, Sugarman J, Winer EP, Iglehart JD, Futreal PA, Rimer BK. Skinner CS, et al. Among authors: schildkraut jm. Genet Test. 2002 Summer;6(2):93-105. doi: 10.1089/10906570260199348. Genet Test. 2002. PMID: 12215248

5

Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States).

Moorman PG, Schildkraut JM, Calingaert B, Halabi S, Vine MF, Berchuck A. Moorman PG, et al. Cancer Causes Control. 2002 Nov;13(9):807-11. doi: 10.1023/a:1020678100977. Cancer Causes Control. 2002. PMID: 12462545

6

High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival.

Lancaster JM, Sayer R, Blanchette C, Calingaert B, Whitaker R, Schildkraut J, Marks J, Berchuck A. Lancaster JM, et al. Among authors: schildkraut j. Clin Cancer Res. 2003 Feb;9(2):762-6. Clin Cancer Res. 2003. PMID: 12576447

7

No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina.

Lancaster JM, Wenham RM, Halabi S, Calingaert B, Marks JR, Moorman PG, Bentley RC, Berchuck A, Schildkraut JM. Lancaster JM, et al. Cancer Epidemiol Biomarkers Prev. 2003 Mar;12(3):226-7. Cancer Epidemiol Biomarkers Prev. 2003. PMID: 12646513 No abstract available.

8

Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls.

Vine MF, Calingaert B, Berchuck A, Schildkraut JM. Vine MF, et al. Gynecol Oncol. 2003 Jul;90(1):75-82. doi: 10.1016/s0090-8258(03)00175-6. Gynecol Oncol. 2003. PMID: 12821345

9

Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer.

Wenham RM, Schildkraut JM, McLean K, Calingaert B, Bentley RC, Marks J, Berchuck A. Wenham RM, et al. Among authors: schildkraut jm. Clin Cancer Res. 2003 Oct 1;9(12):4396-403. Clin Cancer Res. 2003. PMID: 14555511

10

Racial differences in enrolment in a cancer genetics registry.

Moorman PG, Skinner CS, Evans JP, Newman B, Sorenson JR, Calingaert B, Susswein L, Crankshaw TS, Hoyo C, Schildkraut JM. Moorman PG, et al. Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1349-54. Cancer Epidemiol Biomarkers Prev. 2004. PMID: 15298957

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

587 results

Search Page

Filters